Alcon's Newest Antibiotic, Vigamox Ophthalmic Solution, Earns FDA Approval

Article

:Alcon's Newest Antibiotic, Vigamox Ophthalmic Solution, Earns FDA Approval

FORT WORTH, Texas, April 16 /PRNewswire-FirstCall/ -- Alcon, Inc. announces that it received approval from the U.S. Food and Drug Administration (FDA) of its newest antibiotic product, Vigamox (moxifloxacin ophthalmic solution) 0.5 percent, after a six-month review. Vigamox solution contains moxifloxacin, a potent fourth-generation fluoroquinolone antibiotic and is safe and effective for adults and children as young as one year old.

Vigamox solution, dosed only three times a day for seven days, treats bacterial conjunctivitis. Alcon has studied Vigamox solution extensively in three major clinical trials involving more than 1,400 patients.

Moxifloxacin is highly soluble, which allows it to be formulated at a higher concentration (0.5 percent) than other fourth-generation fluoroquinolones. It is very effective against many types of harmful bacteria that infect the surface of the eye. Vigamox solution also shows enhanced coverage of difficult-to-treat Gram-positive bacteria, a class including Staphylococcus and Streptococcus, which account for an estimated 80 percent of eye infections. It is also highly active against Chlamydia, as well as other emerging bacterial threats.

In addition to its therapeutic benefits, Vigamox solution is robust enough to be formulated without the preservative benzalkonium chloride, as a result of the inherent antimicrobial activity of moxifloxacin. It also has a near-neutral pH, resulting in a low incidence of stinging when applied in the eye -- an especially important consideration for children. Furthermore, Vigamox solution provides excellent penetration into ocular tissues. Alcon expects Vigamox solution to be available within several weeks.

Source: Alcon, Inc.

Recent Videos
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Concept images of Far-UVC  (Adobe Stock 316993517 by hopenv)
Related Content